Home
Storia in 2 fonti
Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar
The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.
- ·
cnbc.com
Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar
The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.
- ·
We're raising our Eli Lilly price target — what a difference a quarter makes
The drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications
- ·
fortune.com
Adult obesity rate fell from record high—and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and…
Eli Lilly reported stellar third-quarter earnings yesterday and raised this year’s revenue estimates from $60 billion–$62 billion to $63 billion–$63.5 billion.